LINTONPHARM
1.12.2021 14:02:14 CET | Business Wire | Press release
LintonPharm Co., Ltd., a China-based clinical stage biopharmaceutical company focused on the development of T cell engaging bispecific antibodies for cancer immunotherapy, today announced that the first patient has been dosed in the Company’s Phase 1/2 clinical trial program for catumaxomab (clinicaltrials.gov: NCT04799847 ), a monoclonal bispecific antibody being studied for the treatment of Non-Muscle-Invasive Bladder Cancer (NMIBC) unresponsive to Bacillus Calmette-Guerin (BCG).
“The initiation of our Phase 1 trial of catumaxomab for the treatment of NMIBC is an important step in our clinical program evaluating catumaxomab as targeted therapy in a broad range of cancers”, said Robert Li, PH.D., DABT, Co-founder and CEO of LintonPharm. “Patients with NMIBC BCG failure need new therapies due to the limitations of current treatments which bring poor prognosis, such as high rates of tumor recurrence, bladder dysfunction and lifelong intervention. Based on encouraging pre-clinical data and clinical experience with patients who’ve received catumaxomab in the past through the compassionate use program, we are hopeful that catumaxomab will be a very promising immunotherapy candidate for patients with NMIBC BCG failure.”
A recent publication indicated clinical benefits of catumaxomab as compassionate use in patients with EpCAM-positive recurrent NMIBC. It is noted that catumaxomab was well tolerated and presented promising performance in tumor control [1] . Based on the data and the developmental potential, catumaxomab could provide a feasible, safe, and efficacious therapy for NMIBC patients, if approved.
Bladder cancer is the 10th most commonly diagnosed cancer worldwide, with approximately 573,000 new cases in 2020 and roughly 75 percent are diagnosed as NMIBC [2][3] . Currently, the mainstay treatments of NMIBC include transurethral resection, chemotherapy and intravesical BCG [3] .
About Catumaxomab
Catumaxomab was approved by the European Medicines Agency in 2009 for the treatment of malignant ascites. This bispecific antibody binds to a transmembrane glycoprotein on the tumor cell--the epithelial cell adhesion molecule (EpCAM)--and CD3 on the T cell, and also recruits immune accessory cells through FcγR binding. Catumaxomab destroys tumor cells by engaging T cell and accessory cell mediated cytotoxicity and has the potential to induce long-term vaccinal effects which has been verified in animal models.
Recently, catumaxomab was authorized by regulatory authorities in China, Taiwan (China) and South Korea to conduct a global Phase 3 clinical trial for treating patients with advanced gastric cancer (clinicaltrials.gov: NCT04222114 ).
About LintonPharm
LintonPharm Co., Ltd. is a clinical-stage, research-oriented biopharmaceutical company committed to developing innovative T cell engaging bispecific antibodies with the goal of turning malignant cancers into manageable and possibly curable diseases. LintonPharm has developed multiple bispecific antibody platforms with a great potential of refined safety and efficacy profiles, long-lasting vaccinal effects and CMC efficiency. The current pipeline includes several treatments in development for blood cancer and solid tumors. The leading molecule, catumaxomab is being evaluated in clinical trials for both advanced gastric cancer and non-muscle invasive bladder cancer. For more information, please visit www.lintonpharm.com .
[1]. Ruf P, Bauer HW, Schoberth A, Kellermann C, Lindhofer H (2021). First time intravesically administered trifunctional antibody catumaxomab in patients with recurrent non muscle invasive bladder cancer indicates high tolerability and local immunological activity. Cancer Immunology, Immunotherapy. http://doi.org/10.1007/s00262-021-02930-7 |
[2]. World Health Organization (WHO). Globocan 2020. Global Cancer Observatory. Accessed January 7, 2021. https://gco.iarc.fr/ |
[3]. Kamat AM, Hahn NM, Efstathiou JA, et al. (2016) Bladder cancer. Lancet 2016. 388: 2796-810. http://dx.doi.org/10.1016/S0140-6736(16)30512-8 |
View source version on businesswire.com: https://www.businesswire.com/news/home/20211201005307/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Reply Named EMEA Winner at the 2026 GitHub Services and Channel Partner of the Year Awards30.10.2026 13:23:00 CET | Press release
Reply [EXM, STAR: REY] announced that it has been named the EMEA winner in the 2026 GitHub Services and Channel Partner of the Year Awards, recognising customer outcomes and GitHub ecosystem impact across Europe, the Middle East and Africa. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261030597484/en/ Reply announced that it has been named the EMEA winner in the 2026 GitHub Services and Channel Partner of the Year Awards, recognising customer outcomes and GitHub ecosystem impact across Europe, the Middle East and Africa. Reply helps organisations adopt GitHub and modernise software development. Its capabilities combine large-scale migration, automation and embedded security to bring fragmented development environments into a shared platform, supporting consistent governance and collaboration across engineering teams. A key example is Reply’s collaboration with Nexi, one of Europe’s leading PayTech companies, to transform s
Centralized Supply Chain Services, LLC (CSCS®), Applebee’s®, and IHOP® Recognize 2026 Supplier Partners of the Year30.10.2026 13:00:00 CET | Press release
Pacific Prime Meats and Custom Foods of America recognized for exceptional collaboration, responsiveness and value Centralized Supply Chain Services, LLC (CSCS®), together with Applebee’s® and IHOP®, have named Pacific Prime Meats and Custom Foods of America their 2026 Supplier Partners of the Year, honoring the companies for their collaboration, innovation, and commitment to supporting restaurant success across the Applebee’s and IHOP systems. The awards were presented at the Applebee’s Franchise Conference and IHOP Supplier Summit in Austin, Texas. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261030647942/en/ Pacific Prime Meats was named 2026 Applebee’s Supplier Partner of the Year, recognizing the company’s exceptional responsiveness, agility, and support on behalf of the Applebee’s system. Pacific Prime Meats was named 2026 Applebee’s Supplier Partner of the Year, recognizing the company’s exceptional responsiveness,
Europerfusion 2026: Eurosets Introduces Trilly Baby, the New Oxygenator for Cardiopulmonary Bypass in the Smallest Patients30.10.2026 12:45:00 CET | Press release
Following the acquisition of the CE mark, the device will be introduced across 14 cardiac surgery centers in Europe in January 2027. The launch marks an expansion of the Italian biomedical company's portfolio, consolidating its presence in international markets Eurosets presents Trilly Baby at Europerfusion 2026 (Belgrade, October 30-31), a new oxygenator designed for cardiopulmonary bypass procedures in the smallest patients requiring open-heart cardiac surgery. Engineered to operate with flow rates from 0.1 to 1.8 liters per minute, Trilly Baby represents a further step in the evolution of the Italian biomedical company's cardiopulmonary portfolio. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261030531073/en/ Trilly Baby at Europerfusion 2026. Antonio Petralia, CEO of Eurosets, and Gabriele Pastorelli, Sr. Global Marketing Manager Cardiopulmonary - LATAM Area Manager The device, which is expected to achieve the CE mark b
Men’s Interest in Appearance Is Growing: 36% Say Looking Their Best Matters More Than Five Years Ago, NIQ Finds30.10.2026 11:45:00 CET | Press release
New NIQ insights reveal changing attitudes toward appearance and aging, while purchasing data points to opportunities beyond products marketed specifically to men NielsenIQ (NYSE: NIQ), a global leader in consumer intelligence, today shared findings showing that 36% of men say looking their best, including beauty and skincare, matters more to them than it did five years ago. More than half (54%) say aging well has become more important over the same period. Yet the opportunity for beauty brands may extend beyond products specifically marketed to men. Across 10 Western European markets, sales value of skincare positioned for all genders grew 7% year over year, while male-targeted skincare was flat. The findings suggest that brands should look beyond traditional product positioning to understand men’s needs, shopping behavior, and the products they choose. In its report, The Permission Gap: The Global State of Male Beauty, NIQ examines how social expectations, generational differences an
INSEAD Establishes Thrive Lab With US$3 Million Funding From Google.org and Google DeepMind30.10.2026 10:00:00 CET | Press release
Launched at INSEAD AI Forum Asia, the new Lab is set to advance global academic research on the impact of AI on human connectivity, meaning and wellbeing in work and life INSEAD, The Business School for the World, today announced it has received US$3 million in funding from Google.org and Google DeepMind. The funding will support the Research Lab for Human and Organisational Thriving (INSEAD Thrive Lab), aimed at accelerating global research on how people and organisations can flourish in an era of continuous technological transformation. Artificial intelligence is emerging as the most consequential technology that profoundly shapes how people learn, work, live and interact with one another. While it presents near limitless possibilities, we need to give careful attention to the potential risks. How can we strengthen our human, social and psychological capital amid relentless technological change? And how must our ecosystems of learning – spanning educational, community, and profession
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom